NCT04685135 · OUTCOME

Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation · Source last updated 2026-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

What was measured

Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Analysis population: Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.

Groups in this outcome

Adagrasib

Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).

Docetaxel

Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.

Crossover Adagrasib

Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Adagrasib	298
Docetaxel	140
Crossover Adagrasib	44

Reported measurements

Anemia Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	50	Not reported	Not reported	Not reported	Not reported
Docetaxel	16	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	5	Not reported	Not reported	Not reported	Not reported

Anemia Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	155	Not reported	Not reported	Not reported	Not reported
Docetaxel	74	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	26	Not reported	Not reported	Not reported	Not reported

Anemia Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	74	Not reported	Not reported	Not reported	Not reported
Docetaxel	34	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	7	Not reported	Not reported	Not reported	Not reported

Anemia Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	16	Not reported	Not reported	Not reported	Not reported
Docetaxel	8	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Anemia Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Adagrasib	Not reported	Not reported	Not reported	Not reported
Docetaxel	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	Not reported	Not reported	Not reported	Not reported

Anemia Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	3	Not reported	Not reported	Not reported	Not reported
Docetaxel	8	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	61	Not reported	Not reported	Not reported	Not reported
Docetaxel	33	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	9	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	66	Not reported	Not reported	Not reported	Not reported
Docetaxel	20	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	7	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	71	Not reported	Not reported	Not reported	Not reported
Docetaxel	33	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	10	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	52	Not reported	Not reported	Not reported	Not reported
Docetaxel	23	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	9	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	8	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Lymphocytes count decreased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	40	Not reported	Not reported	Not reported	Not reported
Docetaxel	28	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	9	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	227	Not reported	Not reported	Not reported	Not reported
Docetaxel	61	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	32	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	10	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	8	Not reported	Not reported	Not reported	Not reported
Docetaxel	7	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	4	Not reported	Not reported	Not reported	Not reported
Docetaxel	10	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	8	Not reported	Not reported	Not reported	Not reported
Docetaxel	21	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	2	Not reported	Not reported	Not reported	Not reported

Neutrophils count decreased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	41	Not reported	Not reported	Not reported	Not reported
Docetaxel	28	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	9	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	208	Not reported	Not reported	Not reported	Not reported
Docetaxel	113	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	35	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	74	Not reported	Not reported	Not reported	Not reported
Docetaxel	13	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	6	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	8	Not reported	Not reported	Not reported	Not reported
Docetaxel	3	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	1	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	3	Not reported	Not reported	Not reported	Not reported
Docetaxel	0	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

Platelets count decreased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	4	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Grade 0

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	235	Not reported	Not reported	Not reported	Not reported
Docetaxel	72	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	36	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Grade 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	36	Not reported	Not reported	Not reported	Not reported
Docetaxel	14	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Grade 2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	16	Not reported	Not reported	Not reported	Not reported
Docetaxel	15	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	7	Not reported	Not reported	Not reported	Not reported
Docetaxel	24	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	0	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Grade 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	0	Not reported	Not reported	Not reported	Not reported
Docetaxel	4	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	1	Not reported	Not reported	Not reported	Not reported

White blood cell decreased Missing

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Adagrasib	4	Not reported	Not reported	Not reported	Not reported
Docetaxel	11	Not reported	Not reported	Not reported	Not reported
Crossover Adagrasib	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
50
group Id
OG001
value
16
group Id
OG002
value
5
title
Anemia Grade 0
categories
measurements
group Id
OG000
value
155
group Id
OG001
value
74
group Id
OG002
value
26
title
Anemia Grade 1
categories
measurements
group Id
OG000
value
74
group Id
OG001
value
34
group Id
OG002
value
7
title
Anemia Grade 2
categories
measurements
group Id
OG000
value
16
group Id
OG001
value
8
group Id
OG002
value
3
title
Anemia Grade 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
title
Anemia Grade 4
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
8
group Id
OG002
value
3
title
Anemia Missing
categories
measurements
group Id
OG000
value
61
group Id
OG001
value
33
group Id
OG002
value
9
title
Lymphocytes count decreased Grade 0
categories
measurements
group Id
OG000
value
66
group Id
OG001
value
20
group Id
OG002
value
7
title
Lymphocytes count decreased Grade 1
categories
measurements
group Id
OG000
value
71
group Id
OG001
value
33
group Id
OG002
value
10
title
Lymphocytes count decreased Grade 2
categories
measurements
group Id
OG000
value
52
group Id
OG001
value
23
group Id
OG002
value
9
title
Lymphocytes count decreased Grade 3
categories
measurements
group Id
OG000
value
8
group Id
OG001
value
3
group Id
OG002
value
0
title
Lymphocytes count decreased Grade 4
categories
measurements
group Id
OG000
value
40
group Id
OG001
value
28
group Id
OG002
value
9
title
Lymphocytes count decreased Missing

denoms

counts
group Id
OG000
value
298
group Id
OG001
value
140
group Id
OG002
value
44
units
Participants

description

groups

description
Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).
id
OG000
title
Adagrasib
description
Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.
id
OG001
title
Docetaxel
description
Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).
id
OG002
title
Crossover Adagrasib

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.

reporting Status

POSTED

time Frame

From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

title

Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice